ClinicalTrials.gg
CompletedNCT03586570Updated Nov 23, 2022

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

A Phase 1 interventional study of Aprocitentan 25mg and Placebo in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in United States. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-23.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Sep 2018, 8 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the tolerability, safety, and pharmacokinetics after multiple-dose administration of aprocitentan (25 mg) in healthy Japanese and Caucasian subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be of Caucasian or Japanese ethnicity
  • Signed in a language understandable to the subject prior to any study-mandated procedure
  • (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at Screening
  • Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse rate 45-90 bpm (inclusive), measured on the same arm, after 5 min in the supine position at Screening
  • A woman of is eligible only if the following applies:

Negative serum pregnancy test at Screening,

Negative urine pregnancy test on Day -1,

Agreement to consistently and correctly use a reliable method of from Screening up to at least 30 days after last study treatment administration

Japanese subjects only

  • Subjects must be of native Japanese descent (all parents/grandparents of Japanese descent).
  • Subjects must not have been away from Japan for more than 10 years (at Screening visit).
  • Subject's lifestyle should not have changed significantly since relocation from Japan

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to aprocitentan and/or macitentan.
  • Known to aprocitentan or treatments of the same class, or any of the
  • Pregnant or lactating women
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Aprocitentan

    Drug: Aprocitentan 25mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Oral tablets in strength of 25 mg

  • DrugPlacebo

    Oral tablets matching aprocitentan tablets

06

What researchers measure

Primary outcomes

  1. Cmax during the first and last dosing interval

    Time frame: From study treatment administration to 216 hours after last administration

  2. Time to reach Cmax (tmax) during the first and last dosing interval

    Time frame: From study treatment administration to 216 hours after last administration

  3. AUCτ on the first and last day of study treatment intake

    Time frame: From study treatment administration to 216 hours after last administration

07

Study locations

1 site
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Sep 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2018
First posted
Jul 13, 2018
StartActual
Jul 17, 2018
Primary completionActual
Sep 10, 2018
CompletionActual
Sep 10, 2018
Last update
Nov 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03586570
Responsible party
Sponsor
First posted
Jul 13, 2018
Start date
Jul 17, 2018
Primary completion
Sep 10, 2018
Completion
Sep 10, 2018
Last update
Nov 23, 2022

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprocitentan

Start the discussion